Brimonidine for erythema caused by rosacea

doi:10.1136/dtb.2014.12.0295

Cited by 5 publications

(3 citation statements)

References 8 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 3 , 4 The topical application of brimonidine gel may reduce facial erythema by inducing cutaneous vasoconstriction of rosacea. 3 , 5 Brimonidine, with the characteristics of rapid metabolism and systemic clearance, has no significant affects on the heart rate and blood pressure. 4 However, some medicines, such as tricyclic antidepressants or monoamine oxidase inhibitors, may influence brimonidine's metabolism.…”

Section: Discussionmentioning

confidence: 99%

“…We used brimonidine due to its positive effect in the treatment of rosacea and its insignificant effect on the heart rate and blood pressure. 3 , 4 , 5 PG demonstrates weak expression of beta-adrenergic receptors, which is also a reason to consider brimonidine. 10 We are in favor of the prophylactic use of a topical treatment, such as brimonidine, after surgery to reduce the risk of PG development or recurrence.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Topical brimonidine for pyogenic granuloma after paronychia surgery

2021

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Topical brimonidine for pyogenic granuloma after paronychia surgery

2021

View full text Add to dashboard Cite

“…Recently in 2014, Brimonidine ® , a FDA-approved drug, was proposed for the management of erythematotelangiectatic rosacea as a topical therapy. 21 Brimonidine ® acts by reversing skin vasodilation. Alternative methods to drugs for papulopustular rosacea or erythematotelangiectatic rosacea are based either on the use of dermocosmetic or on the medical devices solutions (laser and intense pulsed light therapies).…”

Section: Discussionmentioning

confidence: 99%

Combination of new multifunctional molecules for erythematotelangiectatic rosacea disorder

Chajra¹,

Nadim²,

Auriol³

et al. 2015

CCID

View full text Add to dashboard Cite

BackgroundRosacea, a common chronic skin disorder, is currently managed by patient education, pharmacological drugs, medical devices (laser and light therapies), and use of proper skin cares. Unfortunately, none of these actual treatments used alone or in combination is curative, and so we proposed a dermocosmetic active ingredient to mitigate some aspects of the rosacea and particularly for erythematotelangiectatic rosacea.MethodsDermocosmetic active ingredient is composed of three glucosylated derivatives of natural plants hydroxybenzoic acid and hydroxycinnamic acids (rosmarinic acid, gallic acid, and caffeic acid). Anti-inflammatory, anti-angiogenesis, and anti-degranulation studies were done on cellular models (keratinocytes, mast cells, and endothelial cells). Efficiency of the active ingredient in comparison to placebo was assessed clinically on human volunteers having erythematotelangiectatic rosacea. The active and placebo were applied topically twice a day for 28 days. Biometrical analyses were done using a siascope tool.ResultsWe found that the active ingredient decreases inflammation (inhibition of interleukin-8 and tumor necrosis factor release), decreases degranulation of mast cells (inhibition of histamine release), and controls angiogenesis mechanism (inhibition of the production of vascular endothelial growth factor and neovessel formation) on cellular models. Study on human volunteers confirmed macroscopically the efficiency of this active ingredient, as we observed no neovessel formation and less visible vessels.ConclusionAlthough rosacea is a skin condition disorder that is difficult to heal, the studies have shown that this active ingredient could be a dermocosmetic support, especially for erythematotelangiectatic rosacea armamentarium. The active ingredient was topically applied on the face for 28 days and improved erythematotelangiectatic rosacea symptoms either by decreasing them (vessels are less visible) or by limiting their development (any neovessels). The active ingredient decreases inflammation (inhibition of interleukin-8 and tumor necrosis factor release), decreases degranulation of mast cells (inhibition of histamine release), and limits the angiogenesis process (inhibition of vascular endothelial growth factor production and neovessel formation).

show abstract

Ivermectin cream for rosacea

Gupta

Daigle

Gupta

et al. 2015

DTB

View full text Add to dashboard Cite

Rosacea is a chronic facial skin disease that mainly occurs in people aged over 30 years. It is common, with an estimated incidence of 1·7 per 1,000 person-years in general practice in the UK.(1,2) Rosacea can cause embarrassment, anxiety, low self-esteem and lack of confidence.(3) A new topical treatment has become available for the treatment of one of the clinical subtypes of rosacea. Ivermectin 10mg/g (1%) cream (Soolantra-Galderma) has received marketing authorisation for the treatment of inflammatory lesions of papulopustular rosacea in adults.(4) Here we review the safety and effectiveness of ivermectin cream in the treatment of rosacea and assess how it compares with standard therapies.

show abstract

Brimonidine for erythema caused by rosacea

Abstract: Brimonidine gel (Mirvaso-Galderma) became available in February of this year for the symptomatic treatment of facial erythema associated with rosacea in adults.1 Here, we review the evidence on brimonidine gel and consider its place in the management of erythema associated with rosacea.

Cited by 5 publications

References 8 publications

Topical brimonidine for pyogenic granuloma after paronychia surgery

Topical brimonidine for pyogenic granuloma after paronychia surgery

Combination of new multifunctional molecules for erythematotelangiectatic rosacea disorder

Ivermectin cream for rosacea

Contact Info

Product

Resources

About